1Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
2Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina
3Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina
4Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina
Correspondence: Dr. Peter J. Greasley, Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 50 Mölndal, Sweden, or Prof. Barry I. Freedman, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053. Email: [email protected] or [email protected]